Literature DB >> 12093313

Prevention of otitis media by vaccination.

Fiona Russell1, Kim Mulholland.   

Abstract

Otitis media (OM) is one of the commonest infections in childhood and a frequent reason for prescribing antibacterials in infancy. However, the increase in prevalence of antibacterial-resistant respiratory bacterial pathogens has not been matched by the development of new antibacterial agents. Bacterial vaccine strategies aim to prevent OM directly and to reduce nasopharyngeal carriage of pneumococci, thereby reducing the likelihood of developing acute OM. Complete protection against OM would require an approach targeting both bacterial and viral agents. Immunisation with a pneumococcal conjugate vaccine provides protection against acute OM caused by pneumococcal serotypes included in the vaccine, reduces serotype-specific pneumococcal carriage, and reduces carriage of penicillin-resistant pneumococci. However, an increase in non-vaccine serotype OM has been observed in vaccinated children, which may limit the overall effectiveness of this vaccine. New vaccines targeting non-typable Haemophilus influenzae and Mycoplasma catarrhalis are in the early stages of development. Efficacy studies with influenza vaccine have shown the most promising results to date in terms of overall reduction in OM episodes. A more substantial reduction in the burden of OM in childhood would require a combination of vaccines that are effective against the bacterial and viral pathogens involved and that can be administered early in infancy.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12093313     DOI: 10.2165/00003495-200262100-00002

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  25 in total

1.  Prevention of pneumococcal disease by vaccination: does serotype replacement matter?

Authors:  B G Spratt; B M Greenwood
Journal:  Lancet       Date:  2000-10-07       Impact factor: 79.321

Review 2.  Viruses in acute otitis media: increasing evidence for clinical significance.

Authors:  O Ruuskanen; M Arola; T Heikkinen; T Ziegler
Journal:  Pediatr Infect Dis J       Date:  1991-06       Impact factor: 2.129

3.  Carriage of pneumococci after pneumococcal vaccination.

Authors:  S K Obaro; R A Adegbola; W A Banya; B M Greenwood
Journal:  Lancet       Date:  1996-07-27       Impact factor: 79.321

4.  Immunization with a pneumococcal capsular polysaccharide vaccine during pregnancy.

Authors:  T J O'Dempsey; T McArdle; S J Ceesay; W A Banya; E Demba; O Secka; M Leinonen; H Käyhty; N Francis; B M Greenwood
Journal:  Vaccine       Date:  1996-07       Impact factor: 3.641

5.  Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group.

Authors: 
Journal:  Pediatrics       Date:  1998-09       Impact factor: 7.124

6.  Immunogenicity and impact on nasopharyngeal carriage of a nonavalent pneumococcal conjugate vaccine.

Authors:  N Mbelle; R E Huebner; A D Wasas; A Kimura; I Chang; K P Klugman
Journal:  J Infect Dis       Date:  1999-10       Impact factor: 5.226

7.  Serum, breast milk, and infant antibody after maternal immunisation with pneumococcal vaccine.

Authors:  N S Shahid; M C Steinhoff; S S Hoque; T Begum; C Thompson; G R Siber
Journal:  Lancet       Date:  1995-11-11       Impact factor: 79.321

Review 8.  Otitis media in developing countries.

Authors:  S Berman
Journal:  Pediatrics       Date:  1995-07       Impact factor: 7.124

9.  Bacterial polysaccharide immune globulin for prophylaxis of acute otitis media in high-risk children.

Authors:  P A Shurin; J M Rehmus; C E Johnson; C D Marchant; S A Carlin; D M Super; G F Van Hare; P K Jones; D M Ambrosino; G R Siber
Journal:  J Pediatr       Date:  1993-11       Impact factor: 4.406

10.  Cost-effectiveness considerations in otitis media treatment.

Authors:  G A Gates
Journal:  Otolaryngol Head Neck Surg       Date:  1996-04       Impact factor: 5.591

View more
  2 in total

Review 1.  Mouse models for the study of mucosal vaccination against otitis media.

Authors:  Albert Sabirov; Dennis W Metzger
Journal:  Vaccine       Date:  2008-02-04       Impact factor: 3.641

Review 2.  Virus-induced secondary bacterial infection: a concise review.

Authors:  Mohamed A Hendaus; Fatima A Jomha; Ahmed H Alhammadi
Journal:  Ther Clin Risk Manag       Date:  2015-08-24       Impact factor: 2.423

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.